<DOC>
	<DOCNO>NCT02227199</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose brentuximab vedotin combine ifosfamide , carboplatin , etoposide treat patient Hodgkin lymphoma come back ( relapse ) respond treatment ( refractory ) . Monoclonal antibody-drug conjugate , brentuximab vedotin , block cancer growth different way target certain cell . Drugs use chemotherapy , ifosfamide , carboplatin , etoposide , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving brentuximab vedotin together ifosfamide , carboplatin , etoposide chemotherapy regimen may kill cancer cell .</brief_summary>
	<brief_title>Brentuximab Vedotin , Ifosfamide , Carboplatin , Etoposide Treating Patients With Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate dose brentuximab vedotin combine ifosfamide , carboplatin etoposide chemotherapy patient relapse refractory Hodgkin lymphoma . II . To gain preliminary assessment efficacy regimen . SECONDARY OBJECTIVES : I . To determine safety toxicity regimen . II . To determine ability proceed peripheral blood stem cell collection follow regimen ( impact regimen stem cell reserve ) . III . To assess impact regimen biomarkers microenvironment Hodgkin lymphoma tumor . OUTLINE : This phase I , dose-escalation study brentuximab vedotin follow phase II study . Patients receive brentuximab vedotin intravenously ( IV ) 30 minute day 1 8 ; ifosfamide IV 24 hour carboplatin IV 1 hour day 2 ; etoposide IV 1 hour day 1-3 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . Patients plan go consolidative high-dose therapy ( HDT ) autologous stem cell transplantation ( ASCT ) may undergo peripheral blood stem cell ( PBSC ) mobilization follow 2nd course study therapy discretion treat physician . After completion study treatment , patient follow every 3 month 1 year every 6 month 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Patients must primary refractory first relapse cluster differentiation 30 ( CD30 ) + Hodgkin lymphoma Patients must measurable disease defined lesion accurately measure two dimension compute tomography ( CT ) , magnetic resonance imaging ( MRI ) , medical photograph ( skin oral lesion ) , plain xray , conventional technique great transverse diameter 1 cm great ; palpable lesion diameter &gt; = 2 cm ; , least 1 lesion must positive positron emission tomography ( PET ) scan ( i.e. , Deauville score 4 ) ; Note : CT scan remain standard evaluation nodal disease Patients must CT chest , abdomen , pelvis PET within 28 day enrollment ; patient evidence lymphadenopathy neck must dedicate CT neck Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ( performance status 2 allow poor performance status think directly secondary patient 's Hodgkin lymphoma [ HL ] ) Absolute neutrophil count ( ANC ) &gt; = 1,500/uL Platelets &gt; = 100,000/uL ( without transfusion growth factor support ) Serum creatinine &lt; 1.5 mg/dl creatinine clearance ( CrCl ) &gt; 60 mL/min Total bilirubin &lt; 2 time upper limit normal ( unless due Gilbert 's syndrome ) Aspartate aminotransferase ( AST ) &lt; 2.5 time upper limit normal All patient must inform investigational nature study give write consent accordance institutional federal guideline Patients must anticipate complete 2 cycle chemotherapy Patients know positive human immunodeficiency virus ( HIV ) Pregnant nursing woman ; men woman reproductive potential may participate unless agree use effective contraceptive method Patients prior malignancy except adequately treat basal cell carcinoma , squamous cell carcinoma skin , breast cervical cancer situ , cancer patient diseasefree 5 year great , unless approve protocol chair cochair Patients know allergy , intolerance , resistance ( i.e. , remission duration le 6 month lack response ) ifosfamide , carboplatin , etoposide Patients evidence active central nervous system lymphoma Patients prior receipt brentuximab vedotin Patients peripheral neuropathy &gt; grade 1 Patients medical condition would contraindicate treatment aggressive chemotherapy ( include active infection , uncontrolled hypertension , congestive heart failure , unstable angina pectoris , myocardial infarction within past 6 month , uncontrolled arrhythmia ) ; patient 's cardiac history questionable , measurement leave ventricular ejection fraction obtain within 42 day prior registration ; patient leave ventricular ejection fraction &lt; 50 % eligible Prior fail ( &lt; 5 x 10^6 CD34/kg ) peripheral blood stem cell ( PBSC ) collection Patients pelvic radiation within 12 month Previous chemotherapy/immunotherapy within 3 week study entry Concurrent use anticancer agent experimental treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>